Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)
Martin H. Schuler, MD, of the University Hospital Essen, discusses findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)
Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with docetaxel in patients with advanced non-small cell lung cancer. (Abstract LBA44)
Mansoor Raza Mirza, MD, of Rigshospitalet, Copenhagen University Hospital, discusses phase III study findings on maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer. (Abstract LBA3)
Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)
Sian A. Pugh, MBBS, of Southampton University Hospital, discusses 6 to 12-year findings on the scheduled use of the CEA tumor marker and CT follow-up to detect recurrence of colorectal cancer. (Abstract 453O)
